Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• OnabotulinumtoxinA-20 U: Likely has a higher participant-assessed success rate at week four compared to placebo (relative risk (RR) 19.45, 95% confidence interval (CI) 8.60 to 43.99; 575 participants, 4 studies; moderate-certainty evidence) and a higher physician-assessed success rate (RR 17.10, 95% CI 10.07 to 29.05; 1339 participants, 7 studies; moderate-certainty evidence).
• AbobotulinumtoxinA-50 U: Demonstrates a higher participant-assessed success rate at week four compared to placebo (RR 21.22, 95% CI 7.40 to 60.56; 915 participants, 6 studies; high-certainty evidence) and a higher physician-assessed success rate (RR 14.93, 95% CI 8.09 to 27.55; 1059 participants, 7 studies; moderate-certainty evidence).
• IncobotulinumtoxinA-20 U: Likely has a higher participant-assessed success rate at week four compared to placebo (RR 66.57, 95% CI 13.50 to 328.28; 547 participants, 2 studies; moderate-certainty evidence) and a higher physician-assessed success rate (RR 134.62, 95% CI 19.05 to 951.45; 547 participants, 2 studies; moderate-certainty evidence).
• OnabotulinumtoxinA-20 U: Probably has a higher incidence of major adverse events compared to placebo (Peto odds ratio (OR) 3.62, 95% CI 1.50 to 8.74; 1390 participants; 8 studies; moderate-certainty evidence). There may be no difference in any adverse events (RR 1.14, 95% CI 0.89 to 1.45; 1388 participants; 8 studies; low-certainty evidence).
• AbobotulinumtoxinA-50 U: Probably has more major adverse events compared to placebo (Peto OR 3.36, 95% CI 0.88 to 12.87; 1294 participants; 7 studies; moderate-certainty evidence). Any adverse event may be more common compared to placebo (RR 1.25, 95% CI 1.05 to 1.49; 1471 participants; 8 studies; low-certainty evidence).
• There is no population types or subgroups information available in the reviewed documents.